Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis

BMC Public Health

Norbert Donner-Banzhoff²  Erika Baum²  Andreas C Sönnichsen⁴  Annette Becker²  Tanja Krones³  Petra Kaufmann-Kolle¹  Oliver Hirsch²  Heidemarie Keller² 

[1]AQUA-Institute for Applied Quality Improvement and Research in Health Care, Göttingen, Germany

[2]Department of General Practice/Family Medicine, Philipps University of Marburg, Karl-von-Frisch-Strasse 4, Marburg, 35043, Germany

[3]Clinical Ethics, University Hospital Zurich & Institute of Biomedical Ethics, University of Zurich, Zurich, Switzerland

[4]Institute of General Practice, Family Medicine and Prevention, Paracelsus Medical University, Salzburg, Austria

关键词: Hydroxymethylglutaryl-CoA Reductase Inhibitors;    Drug prescriptions;    Cardiovascular diseases;    Intention to treat analysis;    Evaluation studies;   

Others  :  1162059
DOI  :  10.1186/1471-2458-13-623

 received in 2013-01-18, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

Background

The prescription of statins is an evidence-based treatment to reduce the risk of cardiovascular events in patients with elevated cardiovascular risk or with a cardiovascular disorder (CVD). In spite of this, many of these patients do not receive statins.

Methods

We evaluated the impact of a brief educational intervention in cardiovascular prevention in primary care physicians’ prescribing behaviour regarding statins beyond their participation in a randomised controlled trial (RCT). For this, prescribing data of all patients > 35 years who were counselled before and after the study period were analysed (each n > 75000). Outcome measure was prescription of Hydroxymethylglutaryl-CoA Reductase Inhibitors (statins) corresponding to patients’ overall risk for CVD. Appropriateness of prescribing was examined according to different risk groups based on the Anatomical Therapeutic Chemical Classification System (ATC codes).

Results

There was no consistent association between group allocation and statin prescription controlling for risk status in each risk group before and after study participation. However, we found a change to more significant drug configurations predicting the prescription of statins in the intervention group, which can be regarded as a small intervention effect.

Conclusion

Our results suggest that an active implementation of a brief evidence-based educational intervention does not lead to prescription modifications in everyday practice. Physician’s prescribing behaviour is affected by an established health care system, which is not easy to change.

Trial registration

ISRCTN71348772

【 授权许可】

   
2013 Keller et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al.: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):S1-S113.
• [2]Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM: Long-term follow-up of the west of scotland coronary prevention study. N Engl J Med 2007, 357(15):1477-1486.
• [3]Gotto AM Jr: Establishing the benefit of statins in low-to-moderate–risk primary prevention: the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Atheroscler Suppl 2007, 8(2):3-8.
• [4]Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med 1995, 333(20):1301-1307.
• [5]van de Steeg-van Gompel CH, Wensing M, De Smet PA: Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial. Eur J Prev Cardiol 2012, 19(2):169-176.
• [6]Bennett KE, Williams D, Feely J: Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 2003, 58(12):835-841.
• [7]Harder S, Fischer P, Krause-Schafer M, Ostermann K, Helms G, Prinz H, Hahmann M, Baas H: Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol 2005, 60(11):797-805.
• [8]Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njolstad I: Whom are we treating with lipid-lowering drugs? Are we following the guidelines? evidence from a population-based study: the tromso study 2001. Eur J Clin Pharmacol 2004, 60(9):643-649.
• [9]Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP: Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol 2009, 8:25. BioMed Central Full Text
• [10]Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A, Degli Esposti E: Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005, 61(3):225-230.
• [11]Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N: Adherence to statin therapy and patients’ cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008, 64(4):425-432.
• [12]JBS: JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91:v1-v52.
• [13]De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003, 24(17):1601-1610.
• [14]Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114(1):82-96.
• [15]Sheridan S, Pignone M, Mulrow C: Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003, 18(12):1039-1052.
• [16]Krones T, Keller H, Sonnichsen A, Sadowski EM, Baum E, Wegscheider K, Rochon J, Donner-Banzhoff N: Absolute cardiovascular disease risk and shared decision making in primary care: A randomized controlled trial. Ann Fam Med 2008, 6(3):218-227.
• [17]O‘Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, et al.: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009, 3:CD001431.
• [18]Wensing M, Broge B, Kaufmann-Kolle P, Andres E, Szecsenyi J: Quality circles to improve prescribing patterns in primary medical care: what is their actual impact? J Eval Clin Pract 2004, 10(3):457-466.
• [19]Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex interventions to improve health. BMJ 2000, 321(7262):694-696.
• [20]Hirsch O, Keller H, Albohn-Kuhne C, Krones T, Donner-Banzhoff N: Satisfaction of patients and primary care physicians with shared decision making. Eval Health Prof 2010, 33(3):321-342.
• [21]Keller H, Krones T, Becker A, Hirsch O, Sonnichsen AC, Popert U, Kaufmann-Kolle P, Rochon J, Wegscheider K, Baum E, et al.: Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. Eur J Prev Cardiol 2012, 19(3):322-329.
• [22]Martirosyan L, Arah OA, Haaijer-Ruskamp FM, Braspenning J, Denig P: Methods to identify the target population: implications for prescribing quality indicators. BMC Health Serv Res 2010, 10:137. BioMed Central Full Text
• [23]Landau S, Everitt BS: A handbook of statistical analyses using SPSS. Boca Raton: Chapman & Hall; 2004.
• [24]World Health Organisation: Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2010.
• [25]Grissom RJ, Kim JJ: Effect sizes for research.A broad practical approach. Mahwah: Lawrence Erlbaum Associates; 2005.
• [26]Ellis PD: The essential guide to effect sizes. Statistical power, meta-analysis, and the interpretation of research results. Cambridge: Cambridge University Press; 2010.
• [27]Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 1979, 6:65-70.
• [28]von Eye A: Configural frequency analysis: Methods, models and applications. Hillsdale: Lawrence Erlbaum Associates; 2002.
• [29]Krauth J: Einführung in die Konfigurationsfrequenzanalyse (KFA) [Introduction to configural frequency analysis]. Beltz: Weinheim; 1993.
• [30]Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM: Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Intern Med 2010, 170(5):470-477.
• [31]Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM: Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007, 32(5):403-407.
• [32]Stafford RS, Monti V, Ma J: Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005, 2(12):e353.
• [33]Manes C, Giacci L, Sciartilli A, D‘Alleva A, De Caterina R: Aspirin overprescription in primary cardiovascular prevention. Thromb Res 2006, 118(4):471-477.
• [34]Bradley CP: Decision making and prescribing patterns–a literature review. Fam Pract 1991, 8(3):276-287.
• [35]Jones MI, Greenfield SM, Bradley CP: Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001, 323(7309):378-381.
• [36]Grol R: Changing physicians’ competence and performance: finding the balance between the individual and the organization. J Contin Educ Health Prof 2002, 22(4):244-251.
• [37]Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 2003, 362(9391):1225-1230.
• [38]Durack-Bown I, Giral P, d‘Ivernois JF, Bazin C, Chadarevian R, Benkritly A, Bruckert E: Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract 2003, 53(496):851-857.
• [39]Ali NS: Prediction of coronary heart disease preventive behaviors in women: a test of the health belief model. Women Health 2002, 35(1):83-96.
• [40]Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, Ahern DK: Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006, 4(3):205-212.
• [41]Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M: When is it cost-effective to change the behavior of health professionals? JAMA 2001, 286(23):2988-2992.
• [42]Vandenbroucke JP: Observational research, randomised trials, and two views of medical science. PLoS Med 2008, 5(3):e67.
• [43]Chini F, Pezzotti P, Orzella L, Borgia P, Guasticchi G: Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC Publ Health 2011, 11:688. BioMed Central Full Text